PrenaTest® ­– Europe's first non-invasive prenatal test (NIPT)

Non-invasive examination for the determination of the fetal trisomies 21, 18 and 13 such as Klinefelter syndrome, Turner syndrome, Triple X syndrome, XYY syndrome and a 22q11.2 microdeletion

Starting from the ninth week of pregnancy (9+0 p.m.), the PrenaTest® is able to determine trisomy 21, trisomies 21, 18 and 13, gonosomal aneuploidies (Turner, triple X, Klinefelter, and XYY syndromes) as well as the 22q11.2 microdeletion, associated with DiGeorge syndrome and velo-cardio-facial syndrome (Shprintzen syndrome), as requested, in blood samples from expectant mothers at risk for fetal aneuploidies. If desired, the gender of the child may also be determined. With its low false-positive rate the PrenaTest® provides precise information for the early diagnosis of abnormalities, thus potentially reducing the number of unnecessary invasive examinations in women who are unaffected. As a result, it acts as a supplement to the non-invasive prenatal diagnostic techniques already in use, but – in comparison with invasive examination methods – it does not involve the risk of procedure-related miscarriage.

 Reliable

Clear result – no risk score   Determination of the cffDNA level after sample receipt

 Rapid

usually in 4 – 6 business days

Safe

Sensitivity 99 %
False-positive rate 0,1 % (T21/18/13)
Test performance in Germany

Portraits_220x148px_Hofmann

Only the original PrenaTest® is exclusively developed and performed in Germany

“You can rely on certified and independently monitored quality in accordance with German and European law combined with the highest levels of scientific expertise. We will support you in your everyday practice. Contact our scientific experts who perform the PrenaTest® every day and who are continually developing it further.”

Dr. rer. medic. Wera Hofmann
Chief Scientific Officer

You can select three PrenaTest® options based on the medical issue

 

Can be used in the case of / followingPrenaTest® Option 1
Trisomy 21,
gender determination
PrenaTest® Option 2
Trisomies 21, 18, 13,
gender determination
PrenaTest® Option 3
Trisomies 21, 18, 13,
Maldistribution of the
sex chromosomes,
gender determination
Single pregnancy
Twin pregnancy
All fertility treatments
(IVF, ICSI etc.)
Test result for option 1 usually in 2 – 6 business days**.
Test result for option 2 & 3 usually in 4 – 6 business days**.
Portraits_220x148px_Ostrowski
Prenatal diagnostics today
„It is no longer conceivable to perform prenatal diagnostics without the PrenaTest® method.“
Dr. med. Thomas von Ostrowski,
Specialist in gynecology and obstetrics Kinderwunsch und Pränatalmedizin Dorsten
(a prenatal practice in Germany)
PrenaTest® is in accordance to the European IVD Directive

The PrenaTest® DAP.plus software used for the biocomputational analysis of PrenaTest® results has been successfully CE-mark certified and approved for the determination of trisomies 21, 18 and 13, as well as gonosomal aneuploidies in accordance with In-Vitro Diagnostic Directive 98/79/EC (List B, Appendix II, IVD medical devices).

Print Friendly
top